Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer
| Autor: | Xiurong Tian, Takashi Sawasaki, Kazushi Shigemasa, Timothy J. O'Brien, Lijun Gu, Hirotoshi Tanimoto, John B. Beard |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Cancer Research Proteases Pathology medicine.medical_specialty Malignancy Polymerase Chain Reaction ST14 Clinical Studies Biomarkers Tumor medicine Humans Matriptase RNA Messenger Stage (cooking) Survival analysis TADG-15 Aged Aged 80 and over Ovarian Neoplasms biology Cell Membrane Ovary Serine Endopeptidases semiquantitative PCR Middle Aged Prognosis medicine.disease Immunohistochemistry ovarian cancer Oncology Cancer research biology.protein Female Ovarian cancer |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Tumour-associated differentially expressed gene-15 (TADG-15/ST14/matriptase/MT-SP1) is a novel member of the transmembrane serine proteases. Previous studies indicated that TADG-15 is overexpressed in ovarian tumours; however, relationships between expression of TADG-15 and clinical characteristics of ovarian cancer remain unclear. The purpose of this study was to examine TADG-15 expression in ovarian cancers and determine any associations with clinicopathological characteristics or patient survival. Immunohistochemical study revealed that TADG-15 was expressed in 50 (56.2%) of 89 ovarian carcinomas, whereas it was not detected in normal ovaries. TADG-15 expression was significantly more common in patients with early stage disease compared with patients with advanced stage diseases (namely, stage I, 24 out of 33: 72.7%; stage II/III/IV, 26 out of 56: 46.4%; P=0.0157). Kaplan-Meier survival curves demonstrated that patients with TADG-15-positive tumours have had substantially longer survival (P=0.0480). The mean value of relative TADG-15 mRNA expression ratio was significantly higher in stage I tumours than in stage II/III/IV tumours (P=0.0053). Increased expression of TADG-15 is frequently detected in early stage cancers, with expression level downregulated during progression of disease. TADG-15 is associated with early stage ovarian cancer and longer patient survival; therefore, it may be a favourable prognostic marker for this malignancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|